Press Release: Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021
Press Release: Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021
Press Release: Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021
新聞稿：Forma Treateutics將於2021年3月30日報告2020年第四季度和年終財務業績並提供業務更新
Forma Therapeutics to Report Fourth Quarter and Year-end 2020 Financial Results and Provide Business Update on March 30, 2021
Forma Treateutics將於2021年3月30日報告2020年第四季度和年終財務業績並提供最新業務
WATERTOWN, Mass.--(BUSINESS WIRE)--March 23, 2021--
馬薩諸塞州沃特敦--(商業資訊)--2021年3月23日--
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that it will release fourth quarter and year-end 2020 financial results Tuesday, March 30, 2021. Forma management will host an investment community conference call at 8 a.m. Eastern Time, on March 30, 2021, to discuss these financial results and provide a business update.
亞洲網加利福尼亞州聖克拉拉3月30日電專注於罕見血液疾病和癌症的臨牀階段生物製藥公司Forma Treateutics Holdings，Inc.(納斯達克代碼：FMTX)今天宣佈，它將公佈2020年第四季度和年終財務業績，週二，2021年3月30日。Fora管理層將於上午8點主持投資界電話會議。東部時間2021年3月30日，討論這些財務業績並提供業務最新情況。
Investors may participate by dialing (833) 301-1146 in the U.S. or Canada, or (914) 987-7386 internationally, and by referring to Conference ID 5893542. A live webcast of the conference call will be available in the "News & Investors" section of Forma's website at www.formatherapeutics.com.
投資者可以通過在美國或加拿大撥打(833)301-1146或在國際上撥打(914)987-7386或通過參考會議ID 5893542來參與。此次電話會議的網絡直播將在Forma公司網站的“新聞與投資者”欄目中播出，網址為www.formaTreateutics.com。
About Forma Therapeutics
關於Forma Treateutics
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.
Forma Treateutics是一家臨牀階段的生物製藥公司，專注於新療法的研究、開發和商業化，以改變罕見血液疾病和癌症患者的生活。我們的研發引擎結合了深刻的生物學洞察力、化學專業知識和臨牀開發能力，創造出具有不同作用機制的候選藥物，專注於具有高度未滿足需求的適應症。我們的工作產生了廣泛的專有計劃組合，有可能為患者帶來深遠的好處。欲瞭解更多信息，請訪問www.FormaTreateutics.com或通過Twitter@FORMAInc.和LinkedIn關注我們。
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005971/en/
在Business wire.com上查看源代碼版本：https://www.businesswire.com/news/home/20210323005971/en/
CONTACT: Investor Contact:
聯繫人：投資者聯繫人：
Mario Corso, +1 781-366-5726
馬裏奧·科爾索電話：+1 781-366-5726
Forma Therapeutics, Inc.
Forma治療公司
mcorso@formatherapeutics.com
郵箱：mcorso@formaTreateutics.com
(END) Dow Jones Newswires
(完)道瓊斯通訊社
March 23, 2021 16:41 ET (20:41 GMT)
2021年3月23日東部時間16：41(格林尼治標準時間20：41)
譯文內容由第三人軟體翻譯。